Retention Rates of Biological Drugs in Spondyloarthritis: A 24-Month Observational Study in Patients Aged 60 Years or Older
Retention of bDMARDs and apremilast in older SpA patients declines over time, with adverse events and inefficacy as key discontinuation drivers. IL-17 inhibitors exhibited better retention, suggesting a potential advantage in this population. Given the impact of comorbidities and treatment safety, personalized treatment strategies and further real-world studies are needed to optimize care in older SpA patients.
Authors
- Giorgio Amato
- Rosario Foti (ORCID: https://orcid.org/0000-0002-7301-8362)
- Roberta Foti (ORCID: https://orcid.org/0000-0002-3074-4508)
- Elisa Visalli (ORCID: https://orcid.org/0000-0002-8213-5528)
- Ylenia Dal Bosco
- Fabio Aiello (ORCID: https://orcid.org/0000-0002-5494-5179)
- Giambattista Privitera (ORCID: https://orcid.org/0009-0009-3272-4840)
- Francesco De Lucia (ORCID: https://orcid.org/0000-0002-2234-511X)
- Maria Gabriella Paolì
- Angelo Montana
Institutions
- Università degli Studi di Enna Kore (IT)
- Policlinico Universitario di Catania (IT)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1007/s40801-025-00514-w
- Citations
- 1
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.67